La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Savara Gestione
Gestione criteri di controllo 3/4
Savara's CEO is Matt Pauls, appointed in Sep 2020, has a tenure of 3.92 years. total yearly compensation is $3.76M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $2.21M. The average tenure of the management team and the board of directors is 3 years and 7.3 years respectively.
Informazioni chiave
Matt Pauls
Amministratore delegato
US$3.8m
Compenso totale
Percentuale dello stipendio del CEO | 15.8% |
Mandato del CEO | 3.9yrs |
Proprietà del CEO | 0.3% |
Durata media del management | 3yrs |
Durata media del Consiglio di amministrazione | 7.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Savara: They Failed Once, But They Are Trying Again
Jun 07The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares
Mar 17Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares
Feb 26Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov 24Savara EPS misses by $0.01
Nov 05Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$75m |
Mar 31 2024 | n/a | n/a | -US$64m |
Dec 31 2023 | US$4m | US$595k | -US$55m |
Sep 30 2023 | n/a | n/a | -US$49m |
Jun 30 2023 | n/a | n/a | -US$43m |
Mar 31 2023 | n/a | n/a | -US$40m |
Dec 31 2022 | US$2m | US$580k | -US$38m |
Sep 30 2022 | n/a | n/a | -US$39m |
Jun 30 2022 | n/a | n/a | -US$39m |
Mar 31 2022 | n/a | n/a | -US$41m |
Dec 31 2021 | US$2m | US$560k | -US$43m |
Sep 30 2021 | n/a | n/a | -US$45m |
Jun 30 2021 | n/a | n/a | -US$46m |
Mar 31 2021 | n/a | n/a | -US$44m |
Dec 31 2020 | US$2m | US$170k | -US$50m |
Sep 30 2020 | n/a | n/a | -US$68m |
Jun 30 2020 | n/a | n/a | -US$69m |
Mar 31 2020 | n/a | n/a | -US$81m |
Dec 31 2019 | US$64k | n/a | -US$78m |
Sep 30 2019 | n/a | n/a | -US$57m |
Jun 30 2019 | n/a | n/a | -US$57m |
Mar 31 2019 | n/a | n/a | -US$47m |
Dec 31 2018 | US$114k | n/a | -US$62m |
Sep 30 2018 | n/a | n/a | -US$58m |
Jun 30 2018 | n/a | n/a | -US$52m |
Mar 31 2018 | n/a | n/a | -US$53m |
Dec 31 2017 | US$75k | n/a | -US$31m |
Compensazione vs Mercato: Matt's total compensation ($USD3.76M) is about average for companies of similar size in the US market ($USD3.30M).
Compensazione vs guadagni: Matt's compensation has increased whilst the company is unprofitable.
AMMINISTRATORE DELEGATO
Matt Pauls (53 yo)
3.9yrs
Mandato
US$3,759,723
Compensazione
Mr. Matthew Pauls, J.D. M.B.A. also known as Matt, is Director at NVN Liquidation Inc. He serves as Director of Soleno Therapeutics, Inc. since August 15, 2023 and is its Lead Independent Director aince Au...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Chairman & CEO | 3.9yrs | US$3.76m | 0.31% $ 2.2m | |
CFO, Chief Administrative Officer & Secretary | 7.8yrs | US$1.52m | 0.050% $ 358.2k | |
Chief Operating Officer | 1.5yrs | US$2.66m | 0% $ 0 | |
Senior VP & General Counsel | 6.4yrs | Nessun dato | Nessun dato | |
Chief Business Officer | 3.8yrs | Nessun dato | 0.071% $ 507.9k | |
Head of Clinical Operations | 3.3yrs | Nessun dato | Nessun dato | |
Senior Vice President of Global Regulatory Affairs & Quality Assurance | 3yrs | Nessun dato | Nessun dato | |
Executive Vice President of Global Technical Operations | 2.9yrs | Nessun dato | Nessun dato | |
Chief Medical Officer | 1.8yrs | US$698.69k | 0.0061% $ 43.5k | |
Executive Vice President of Global Commercial | 1.6yrs | Nessun dato | Nessun dato | |
Senior VP of Global Medical Affairs | 1.3yrs | Nessun dato | Nessun dato | |
Executive VP and Head of Clinical Development & Clinical Operations | less than a year | Nessun dato | Nessun dato |
3.0yrs
Durata media
56yo
Età media
Gestione esperta: SVRA's management team is considered experienced (3 years average tenure).
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Chairman & CEO | 7.3yrs | US$3.76m | 0.31% $ 2.2m | |
Independent Director | 7.3yrs | US$158.13k | 1.34% $ 9.6m | |
Lead Independent Director | 10.8yrs | US$155.13k | 0.10% $ 732.3k | |
Independent Director | 13.8yrs | US$149.13k | 0.0077% $ 55.4k | |
Independent Director | 15.5yrs | US$157.63k | 0% $ 0 | |
Member of Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
Member of Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
Member of Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
Independent Director | 4.7yrs | US$155.63k | 0% $ 0 | |
Member of Clinical Advisory Board | 3.6yrs | Nessun dato | Nessun dato | |
Member of Clinical advisory Board | 1.6yrs | Nessun dato | Nessun dato |
7.3yrs
Durata media
61.5yo
Età media
Consiglio di amministrazione esperto: SVRA's board of directors are considered experienced (7.3 years average tenure).